ATE499112T1 - Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten - Google Patents

Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten

Info

Publication number
ATE499112T1
ATE499112T1 AT06824878T AT06824878T ATE499112T1 AT E499112 T1 ATE499112 T1 AT E499112T1 AT 06824878 T AT06824878 T AT 06824878T AT 06824878 T AT06824878 T AT 06824878T AT E499112 T1 ATE499112 T1 AT E499112T1
Authority
AT
Austria
Prior art keywords
vaccine
infectious diseases
immunomodulatory compounds
against infectious
therapy against
Prior art date
Application number
AT06824878T
Other languages
English (en)
Inventor
Justin Bertlett
George Muller
Peter Schafer
Christine Galutian
Angus Dalgleish
Brendan Meyer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ATE499112T1 publication Critical patent/ATE499112T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06824878T 2005-09-01 2006-08-31 Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten ATE499112T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71282305P 2005-09-01 2005-09-01
PCT/US2006/034271 WO2007028047A2 (en) 2005-09-01 2006-08-31 Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy

Publications (1)

Publication Number Publication Date
ATE499112T1 true ATE499112T1 (de) 2011-03-15

Family

ID=37806889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06824878T ATE499112T1 (de) 2005-09-01 2006-08-31 Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten

Country Status (14)

Country Link
US (2) US8715677B2 (de)
EP (2) EP2301535B1 (de)
JP (2) JP2009507030A (de)
AT (1) ATE499112T1 (de)
CA (1) CA2621136C (de)
CY (1) CY1112325T1 (de)
DE (1) DE602006020300D1 (de)
DK (1) DK1928492T3 (de)
ES (2) ES2359162T3 (de)
HR (1) HRP20110348T1 (de)
PL (1) PL1928492T3 (de)
RS (1) RS51840B (de)
SI (1) SI1928492T1 (de)
WO (1) WO2007028047A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090068210A1 (en) * 2007-07-09 2009-03-12 Munshi Nikhil C Immunotherapy for hematological malignancies
US9200253B1 (en) * 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
JP5637852B2 (ja) 2007-09-26 2014-12-10 セルジーン コーポレイション ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
WO2009131730A2 (en) 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
MX361467B (es) 2008-10-29 2018-12-06 Celgene Corp Compuestos de isoindolina para uso en el tratamiento de cancer.
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
EP3199149A1 (de) 2009-05-19 2017-08-02 Celgene Corporation Formulierungen von 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion
AU2010333767A1 (en) 2009-12-22 2012-07-05 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
MX347928B (es) 2011-01-10 2017-05-19 Celgene Corp Derivados de fenetilsulfona isoindolina y su uso.
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2014526508A (ja) 2011-09-14 2014-10-06 セルジーン コーポレイション シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
BR112014015923B1 (pt) 2011-12-27 2022-02-01 Amgen (Europe) GmbH Comprimidos revestidos de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metano-sulfoniletil]-4 - acetilaminoisoindolina-1,3-diona
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (de) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modifizierte polynukleotide
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US9540340B2 (en) 2013-01-14 2017-01-10 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
EP2764866A1 (de) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Hemmer der nedd8-aktivierenden Enzyme
DK2961388T3 (da) * 2013-03-01 2019-07-08 Astex Pharmaceuticals Inc Kombinationer af lægemidler
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201507759WA (en) 2013-04-02 2015-10-29 Celgene Corp Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
EP2801364A1 (de) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonellenstamm zur Verwendung bei der Behandlung und/oder Vorbeugung von Krebs
EP2815749A1 (de) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
JP2017523166A (ja) 2014-07-11 2017-08-17 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ヒト免疫不全ウイルスｉ（ｈｉｖ）の病理学的影響を減少及び／若しくは遅延させるか又は後天性免疫不全症候群（ａｉｄｓ）を発症するリスクを低減させる方法
JP2018515603A (ja) 2015-05-04 2018-06-14 ビオノル・イムノ・アクシェセルスカプＢｉｏｎｏｒ Ｉｍｍｕｎｏ ＡＳ Ｈｉｖワクチン用の投薬レジメン
TWI727211B (zh) * 2018-09-27 2021-05-11 大江生醫股份有限公司 紅菽草萃取物用於提升玻尿酸合成酶之基因表現量的用途
WO2021261635A1 (ko) * 2020-06-26 2021-12-30 대한민국(농림축산식품부 농림축산검역본부장) 신규 면역증강제 및 이를 포함하는 백신 조성물
CN119868399B (zh) * 2025-03-21 2025-07-11 华南农业大学 杂色曲霉胞外多糖avp141-a在制备抗石斑鱼虹彩病毒的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (fr) 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
CA2013966C (en) 1989-04-05 2000-03-07 Peter Y. S. Fung Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
CA2128331A1 (en) * 1992-01-21 1993-07-22 Julia L. Greenstein Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5728385A (en) * 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE69739802D1 (de) 1996-07-24 2010-04-22 Celgene Corp Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
ES2315435T3 (es) 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
ES2243052T3 (es) 1998-03-16 2005-11-16 Celgene Corporation Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
TR200102688T2 (tr) 1999-03-18 2002-01-21 Celgene Corporation İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları.
AU2593701A (en) * 1999-12-21 2001-07-03 Regents Of The University Of California, The Method for preventing an anaphylactic reaction
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
CA2482924A1 (en) * 2002-04-19 2003-10-30 Endocyte, Inc. Adjuvant enhanced immunotherapy
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CN1981761B (zh) * 2002-05-17 2011-10-12 细胞基因公司 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物
JP2006503110A (ja) * 2002-10-09 2006-01-26 トーラーレックス， インク． エフェクタｔ細胞または制御性ｔ細胞に選択的に結合する分子およびその使用方法
WO2004078928A2 (en) * 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
US20050048054A1 (en) * 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table

Also Published As

Publication number Publication date
EP1928492B1 (de) 2011-02-23
HRP20110348T1 (hr) 2011-07-31
WO2007028047A3 (en) 2007-06-14
CA2621136C (en) 2014-10-14
US8715677B2 (en) 2014-05-06
DK1928492T3 (da) 2011-06-06
ES2485316T3 (es) 2014-08-13
JP5796040B2 (ja) 2015-10-21
JP2009507030A (ja) 2009-02-19
CY1112325T1 (el) 2015-12-09
RS51840B (sr) 2012-02-29
DE602006020300D1 (de) 2011-04-07
US20120190110A1 (en) 2012-07-26
EP1928492A2 (de) 2008-06-11
EP2301535B1 (de) 2014-05-28
WO2007028047A2 (en) 2007-03-08
PL1928492T3 (pl) 2011-09-30
CA2621136A1 (en) 2007-03-08
SI1928492T1 (sl) 2011-09-30
US20070048327A1 (en) 2007-03-01
JP2013241424A (ja) 2013-12-05
ES2359162T3 (es) 2011-05-19
EP2301535A1 (de) 2011-03-30

Similar Documents

Publication Publication Date Title
ATE499112T1 (de) Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA200601671A1 (ru) Идентификация собственных и чужеродных антигенов, вовлечённых в аутоиммунные заболевания
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
CY1111812T1 (el) Ανθρωπινα εξουδετερωτικα αντι-ifn-γ αντισωματα ως εκλεκτικοι αναστολεις του μονοπατιου της ifn-γ
ATE426412T1 (de) Adjuvante influenza-vakzine
ATE473760T1 (de) Monoklonale antikörper gegen den hepatozyten- wachstumsfaktor
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
CY1109914T1 (el) Μαλακες καψουλες που περιλαμβανουν υδροχλωρικη πανολοσετρονη και εχουν βελτιωμενη σταθεροτητα και βιοδιαθεσιμοτητα
WO2007079190A3 (en) Device and method for enhancing immune response by electrical stimulation
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
SE0302312D0 (sv) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
SE0501903L (sv) Borföreningar användbara vid BNCT
ATE530569T1 (de) Assays zum nachweis von tuberkulose- antigenen, und impfstoffe
EP1835931A4 (de) Alpha thymosin peptide als krebsvakzine-adjuvantien
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1928492

Country of ref document: EP